Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics

Published:2018-03-29 Issue:4 Volume:12 Page:3658-3670
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Li Lian,Yang Jiyuan,Wang Jiawei,Kopeček Jindřich^ORCID

Funder

National Cancer Institute

Huntsman Cancer Institute

National Institute of General Medical Sciences

Bastion Biologics

University of Utah Research Foundation

Publisher

American Chemical Society (ACS)

Subject

General Physics and Astronomy,General Engineering,General Materials Science

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.8b00797

Reference39 articles.

1. Global cancer statistics, 2012

2. B lymphocytes: how they develop and function

3. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

4. A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydrophilic biomaterials: From crosslinked and self-assembled hydrogels to polymer-drug conjugates and drug-free macromolecular therapeutics;Journal of Controlled Release;2024-09

2. Clustering of the Membrane Protein by Molecular Self-Assembly Downregulates the Signaling Pathway for Cancer Cell Inhibition;Nano Letters;2024-08-19

3. Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors;Drug Delivery and Translational Research;2024-05-27

4. Cell surface patching via CXCR4-targeted nanothreads for cancer metastasis inhibition;Nature Communications;2024-03-29

5. Clinical efficacy of anti-CD20 antibodies in autoimmune diseases;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3